Diagnostic role of microRNA-125b for hepatocellular carcinoma
Diagnostic role of microRNA-125b for hepatocellular carcinoma
复制标题
microRNA-125b对肝细胞癌的诊断作用
DOI：
10.1016/j.hbpd.2019.06.009
复制
发表时间：
2019
影响因子：
3.3
通讯作者：
Chen Juxiang
中科院分区：
文献类型：
--
作者：
Li Feng;Bao Quanwa;Jiang Liuyiqi;Huang Qilin;Zhang Xu;Chen Juxiang
据估计，2018年全球新增肝癌病例841 000例，相关死亡782 000例，位列第六大常见癌症和第四大癌症相关死亡原因[1]。肝细胞癌约占总病例的90%，是最常见的原发性肝癌类型，也是目前全球公共卫生面临的主要挑战[1]。大多数肝细胞癌患者在确诊时往往处于晚期，错过了最佳治疗方法，预后较差。甲胎蛋白(AFP)是目前应用最广泛的肝细胞癌诊断血清标志物，但其诊断的准确性并不理想，对早期肝癌的敏感性为53%，特异性为90%[2]。近年来，大量研究报道，microRNA-125b(miR-125b)可能成为肝细胞癌潜在的诊断标志物[3-8]。MiR-125家族由miR-125a、miR-125b-1和miR-125b-2组成，与癌细胞的分化、增殖、侵袭和转移密切相关。然而，miR-125b的诊断准确性仍然不一致。
It is estimated that there was 841 0 0 0 new cases of liver cancer and 782 0 0 0 associated deaths worldwide in 2018, ranking as the sixth most common cancer and the fourth leading cause of cancer-related deaths [1]. With approximately 90% of total cases, hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer, and is a major public global health challenge at present [1]. The majority of HCC patients are usually at advanced stages when diagnosed, which misses the optimal treatment and prognosis is poor. Alpha-fetoprotein (AFP) is the most widely applied diagnostic serum biomarker to detect HCC at present; however, the diagnostic accuracy of AFP is unsatisfactory, with sensitivity of 53% and specificity of 90% for early stage HCC [2]. Recently, plenty of studies reported that microRNA-125b (miR-125b) might function as potential diagnostic biomarker in HCC [3-8]. miR-125 family, consisting of miR-125a, miR-125b-1, and miR-125b-2, is closely associated with differentiation, proliferation, invasion, and metastasis of cancer cells. However, the diagnostic accuracy of miR-125b remains inconsistent.